# EDGAR Filing Document

**Accession Number:** 0001410830
**File Stem:** 0000902664-25-005287
**Filing Date:** 2025-12
**Character Count:** 9781
**Document Hash:** eb7e7db3f9d3e5d3cc92d712c178ae4e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000902664-25-005287.hdr.sgml**: 20251215

**ACCESSION NUMBER**: 0000902664-25-005287

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251215

**DATE AS OF CHANGE**: 20251215

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zentalis Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001725160
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 823607803
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91478
- **FILM NUMBER:** 251572501

**BUSINESS ADDRESS:**
- **STREET 1:** 10275 SCIENCE CENTER DRIVE
- **STREET 2:** SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 263-4333

**MAIL ADDRESS:**
- **STREET 1:** 10275 SCIENCE CENTER DRIVE
- **STREET 2:** SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zentalis Pharmaceuticals, LLC
- **DATE OF NAME CHANGE:** 20200107

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zeno Pharma, LLC
- **DATE OF NAME CHANGE:** 20171212
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Matrix Capital Management Company, LP
- **CENTRAL INDEX KEY:** 0001410830

**ORGANIZATION NAME:**
- **EIN:** 043475951
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 3 PLEASANT STREET, SUITE 400
- **STREET 2:** C/O MATRIX CAPITAL MANAGEMENT
- **CITY:** PORTSMOUTH
- **STATE:** NH
- **ZIP:** 03801
- **BUSINESS PHONE:** 781-522-4948

**MAIL ADDRESS:**
- **STREET 1:** 3 PLEASANT STREET, SUITE 400
- **STREET 2:** C/O MATRIX CAPITAL MANAGEMENT
- **CITY:** PORTSMOUTH
- **STATE:** NH
- **ZIP:** 03801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Matrix Capital Management Company, LLC
- **DATE OF NAME CHANGE:** 20070827

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Zentalis Pharmaceuticals, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**98943L107**

*(CUSIP Number)*

**Gregory A. Brown**<br>Matrix Capital Management Company LP<br>1000 Winter Street, Suite 4500<br>Waltham MA 02451<br>(603) 956-9145

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/15/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **98943L107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Matrix Capital Management Company, LP** | Name of reporting person<br>**Matrix Capital Management Company, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**6459973.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**6459973.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**6459973.00** | Aggregate amount beneficially owned by each reporting person<br>**6459973.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.98%** | Percent of class represented by amount in Row (11)<br>**9.98%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

| **CUSIP No.** | **98943L107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**David E. Goel** | Name of reporting person<br>**David E. Goel** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**6459973.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**6459973.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**6459973.00** | Aggregate amount beneficially owned by each reporting person<br>**6459973.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.98%** | Percent of class represented by amount in Row (11)<br>**9.98%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
Zentalis Pharmaceuticals, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121

The following constitutes Amendment No. 2 ("Amendment No. 2") to the Schedule 13D filed by the undersigned on June 3, 2022 (the "Original Schedule 13D"), as amended by Amendment No. 1 to the Original Schedule 13D filed by the undersigned with the Securities and Exchange Commission on June 20, 2023 ("Amendment No. 1" and the Original Schedule 13D as amended by Amendment No. 1, the "Schedule 13D"). This Amendment No. 2 amends and restates Items 4 and 5(a)-(c). Capitalized terms used herein and not otherwise defined in this Amendment No. 2 have the meanings set forth in the Schedule 13D.

**Item 4. Purpose of Transaction**

On December 15, 2025, Karan Takhar, a Senior Managing Director of the Investment Manager, resigned from the board of directors of the Issuer.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by each Reporting Person. The percentages used in this Schedule 13D are calculated based upon 64,750,779 shares of Common Stock outstanding as of December 15, 2025, which is the difference obtained by subtracting (i) 7,500,000 shares of Common Stock sold to the Issuer in the Repurchase (as defined below) from (ii) the 72,250,779 shares of Common Stock outstanding as of November 1, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 10, 2025.

**(b)**
See rows (7) through (10) of the cover pages to this Schedule 13D for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

**(c)**
On December 15, 2025, the Matrix Fund agreed to sell and the Issuer agreed to repurchase 7,500,000 shares of Common Stock from the Matrix Fund at a price of $1.33 per share (the "Repurchase"). The Repurchase closed on December 15, 2025. Except for the Repurchase, no transactions in the shares of Common Stock have been effected by the Reporting Persons during the past sixty (60) days.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Matrix Capital Management Company, LP

**Signature:** /s/ Gregory A. Brown

**Name/Title:** Gregory A. Brown, General Counsel, Chief Compliance Officer

**Date:** 12/15/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** David E. Goel

**Signature:** /s/ David E. Goel

**Name/Title:** David E. Goel, Individually

**Date:** 12/15/2025